|
Dr. Patou is an Executive Partner at MPM Capital and has been a member of Oscient's Board of Directors since 2005. Previously, Dr. Patou was Executive Vice President and Chief Medical Officer of Oscient following the merger with GeneSoft Pharmaceuticals in 2004. As President of Genesoft, Dr. Patou was instrumental in applying for and obtaining FDA approval of the Company's lead antibiotic product, FACTIVE. Prior to joining Genesoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as a Senior Vice President & Director, Project and Portfolio Management, managing all of the company's pharmaceutical development projects, including FACTIVE. Dr. Patou also served as Director and Vice President of Anti-Infective Development where he managed the development of a broad line of anti-infective products, including oral, IV and topical antibiotics. Dr. Patou is a member of the Board at Xenon Pharmaceuticals and serves as the chair of the Scientific Advisory Board at Cerimon Pharmaceuticals. He has held a number of academic appointments at University College & Middlesex School of Medicine in London and holds B.Sc., M.B. B.S. and M.D. degrees from University College London. | 